PAVmed Inc. entered into subscription agreements for the private placement of 13,625 series A convertible preferred stock at an issue price of $1,000 per share for gross proceeds of $13,625,000 on March 7, 2023. The transaction included participation certain accredited investors. In connection with the offering the company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock with the Secretary of State of the State of Delaware.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.65 USD | -8.33% | -12.23% | -59.95% |
May. 14 | Transcript : PAVmed Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 07 | Pavmed Inc. Appoints Dennis Matheis to Board of Directors | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-59.95% | 15.56M | |
+10.22% | 223B | |
+12.99% | 194B | |
+18.09% | 141B | |
+28.66% | 109B | |
+1.33% | 64.85B | |
+14.70% | 52.7B | |
+6.68% | 51.77B | |
+8.29% | 44.12B | |
+2.60% | 36.21B |
- Stock Market
- Equities
- PAVM Stock
- News PAVmed Inc.
- PAVmed Inc. announced that it has received $13.625 million in funding